194 related articles for article (PubMed ID: 26204790)
1. Bronchiolitis obliterans syndrome due to donor-specific HLA-antibodies.
Kauke T; Kneidinger N; Martin B; Dick A; Schneider C; Schramm R; Meimarakis G; Preissler G; Eickelberg O; von Dossow V; Behr J; Hatz R; Neurohr C; Winter H
Tissue Antigens; 2015 Sep; 86(3):178-85. PubMed ID: 26204790
[TBL] [Abstract][Full Text] [Related]
2. De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation.
Safavi S; Robinson DR; Soresi S; Carby M; Smith JD
J Heart Lung Transplant; 2014 Dec; 33(12):1273-81. PubMed ID: 25130554
[TBL] [Abstract][Full Text] [Related]
3. De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation.
Morrell MR; Pilewski JM; Gries CJ; Pipeling MR; Crespo MM; Ensor CR; Yousem SA; D'Cunha J; Shigemura N; Bermudez CA; McDyer JF; Zeevi A
J Heart Lung Transplant; 2014 Dec; 33(12):1288-94. PubMed ID: 25443870
[TBL] [Abstract][Full Text] [Related]
4. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation.
Lobo LJ; Aris RM; Schmitz J; Neuringer IP
J Heart Lung Transplant; 2013 Jan; 32(1):70-7. PubMed ID: 23260706
[TBL] [Abstract][Full Text] [Related]
5. De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation.
Tikkanen JM; Singer LG; Kim SJ; Li Y; Binnie M; Chaparro C; Chow CW; Martinu T; Azad S; Keshavjee S; Tinckam K
Am J Respir Crit Care Med; 2016 Sep; 194(5):596-606. PubMed ID: 26967790
[TBL] [Abstract][Full Text] [Related]
6. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome.
Palmer SM; Davis RD; Hadjiliadis D; Hertz MI; Howell DN; Ward FE; Savik K; Reinsmoen NL
Transplantation; 2002 Sep; 74(6):799-804. PubMed ID: 12364858
[TBL] [Abstract][Full Text] [Related]
7. Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation.
Smith JD; Ibrahim MW; Newell H; Danskine AJ; Soresi S; Burke MM; Rose ML; Carby M
J Heart Lung Transplant; 2014 Oct; 33(10):1074-82. PubMed ID: 24954882
[TBL] [Abstract][Full Text] [Related]
8. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of antibodies to lung self-antigens (Kα1 tubulin and collagen V) and donor specific antibodies to HLA in lung transplant recipients and implications for lung transplant outcomes: Single center experience.
Rao U; Sharma M; Mohanakumar T; Ahn C; Gao A; Kaza V
Transpl Immunol; 2019 Jun; 54():65-72. PubMed ID: 30794945
[TBL] [Abstract][Full Text] [Related]
10. Pre-transplant presence of antibodies to MICA and HLA class I or II are associated with an earlier onset of bronchiolitis obliterans syndrome in lung transplant recipients.
Lyu DM; Grazia TJ; Benson AB; Cagle LR; Freed BM; Zamora MR
Clin Transpl; 2012; ():237-46. PubMed ID: 23721028
[TBL] [Abstract][Full Text] [Related]
11. Early donor-specific antibodies in lung transplantation: risk factors and impact on survival.
Ius F; Sommer W; Tudorache I; Kühn C; Avsar M; Siemeni T; Salman J; Hallensleben M; Kieneke D; Greer M; Gottlieb J; Haverich A; Warnecke G
J Heart Lung Transplant; 2014 Dec; 33(12):1255-63. PubMed ID: 25070908
[TBL] [Abstract][Full Text] [Related]
12. The Presence of Pretransplant HLA Antibodies Does Not Impact the Development of Chronic Lung Allograft Dysfunction or CLAD-Related Death.
Zazueta OE; Preston SE; Moniodis A; Fried S; Kim M; Townsend K; Wood I; Boukedes S; Guleria I; Camp P; El-Chemaly S; Rosas IO; Chandraker A; Milford E; Goldberg HJ
Transplantation; 2017 Sep; 101(9):2207-2212. PubMed ID: 27893614
[TBL] [Abstract][Full Text] [Related]
13. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome.
Smith MA; Sundaresan S; Mohanakumar T; Trulock EP; Lynch JP; Phelan DL; Cooper JD; Patterson GA
J Thorac Cardiovasc Surg; 1998 Nov; 116(5):812-20. PubMed ID: 9806388
[TBL] [Abstract][Full Text] [Related]
14. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
[TBL] [Abstract][Full Text] [Related]
15. Influence of human leukocyte antigen mismatching on bronchiolitis obliterans syndrome in lung transplantation.
Hayes D; Black SM; Tobias JD; Kopp BT; Kirkby SE; Mansour HM; Whitson BA
J Heart Lung Transplant; 2016 Feb; 35(2):186-94. PubMed ID: 26496787
[TBL] [Abstract][Full Text] [Related]
16. Lung transplantation in patients with pretransplantation donor-specific antibodies detected by Luminex assay.
Brugière O; Suberbielle C; Thabut G; Lhuillier E; Dauriat G; Metivier AC; Gautreau C; Charron D; Mal H; Parquin F; Stern M
Transplantation; 2013 Mar; 95(5):761-5. PubMed ID: 23296148
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
[TBL] [Abstract][Full Text] [Related]
18. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation.
Hachem RR; Yusen RD; Meyers BF; Aloush AA; Mohanakumar T; Patterson GA; Trulock EP
J Heart Lung Transplant; 2010 Sep; 29(9):973-80. PubMed ID: 20558084
[TBL] [Abstract][Full Text] [Related]
19. De-novo donor-specific anti-HLA antibodies 30 days after lung transplantation are associated with a worse outcome.
Le Pavec J; Suberbielle C; Lamrani L; Feuillet S; Savale L; Dorfmüller P; Stephan F; Mussot S; Mercier O; Fadel E
J Heart Lung Transplant; 2016 Sep; 35(9):1067-77. PubMed ID: 27373824
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of current strategies for surveillance and management of donor-specific antibodies: Single-center study.
Sullivan D; Ahn C; Gao A; Lacelle C; Torres F; Bollineni S; Banga A; Mullins J; Mohanka M; Ring S; Wait M; Peltz M; Duddupudi P; Surapaneni D; Kaza V
Clin Transplant; 2018 Jul; 32(7):e13285. PubMed ID: 29774598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
